Possibilities of non-antibacterial therapy of community-acquired pneumonia
https://doi.org/10.18093/0869-0189-2012-0-2-99-101
Abstract
Possibilities of non-antibacterial therapy of community-acquired pneumonia.
About the Authors
N. A. Syomash
ФГБУ "ЦНИИ туберкулеза" РАМН
Russian Federation
Russian Federation
A. S. Belevsky
ФУВ "РНИМУ им. Н.И.Пирогова"
Russian Federation
Russian Federation
N. I. Vyaz'menova
ГБУ здравоохранения "ГП № 39" Департамента здравоохранения Москвы
Russian Federation
Russian Federation
References
1. Синопальников А.И. Внебольничная пневмония у взрослых. Consilium medicum 2007; 9 (3): 3–8.
2. Rodriguez A., Lisboa T, Blot S. et al. Mortality in ICU patients with bacterial community-acquired pneumonia: when antibiotics are not enough. Intens. Care Med. 2009, 35 (3): 430–438.
3. Siempos I.I., Vardakas K.Z., Korterides P., Falagas M.E. Adjunctive therapies for community-acquired pneumonia: a systematic review. J. Antimicrob. Chemother. 2008, 62 (4): 661–668.
4. Salluh J.I., Rovoa P., Soares M. et al. The role of corticosteroids in severe community-acquired pneumonia: a systematic review. Crit. Care 2008; 12 (3): R76.
5. Авдеев С.Н. Осложнения внебольничной пневмонии. В кн.: Чучалин А.Г., Синопальников А.И., Чернеховская Н.Е. (ред.). Пневмония. М.: Экономика и информатика; 2002. 134–181.
6. Laterre P.F., Garber G., Levy H. et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit. Care Med. 2005; 33 (5): 952–961.
7. Nelson S., Belknap S.M., Carlson R.W. et al. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment hospitalized patients with community-acquired pneumonia. J. Infect. Dis.1998; 178 (4): 1075–1080.
8. Root R.K., Lodato R.F., Patrick W. et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit. Care Med. 2003; 31 (2): 367–373.
9. Mortensen E.M., Restrepo M.I., Anzueto A., Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir. Res. 2005; 6: 82.
10. Mortensen E.M., Restrepo M.I., Anzueto A., Pugh J. The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalized with community-acquired pneumonia. BMC Pulm. Med. 2005; 5: 12.
11. Аляви А.Л., Курбанова Г.А. Состояние обмена оксида азота при включении N-ацетилцистеина в комплексную терапию больных внебольничной пневмонией. Пробл. туб. и бол. легких. 2007; 9: 20–24.
12. Авдеев С.Н., Батын С.З., Мержоева З.М., Чучалин А.Г. Высокие дозы N- ацетилцистеина при остром респираторном дистресс-синдроме. Пульмонология. 2010; 3: 31–38.
Review
For citations:
Syomash N.A., Belevsky A.S., Vyaz'menova N.I. Possibilities of non-antibacterial therapy of community-acquired pneumonia. PULMONOLOGIYA. 2012;(2):99-101. (In Russ.) https://doi.org/10.18093/0869-0189-2012-0-2-99-101
Views:
749
Email this article 